Price to sales forward of Relay Therapeutics, Inc. – NASDAQ:RLAY
This article provides financial information for Relay Therapeutics, Inc. (NASDAQ: RLAY), focusing on its forward price-to-sales ratio. It presents various financial data points and market information related to the company on the TradingView platform. The content is brief, primarily serving as a data display for the stock's financial performance.
Price to book forward of Relay Therapeutics, Inc. – NASDAQ:RLAY
This article provides financial performance data for Relay Therapeutics, Inc. (NASDAQ: RLAY), specifically focusing on its forward price-to-book ratio. The content is hosted on TradingView, an investment analysis platform, indicating that the information is intended for investors and market analysis.
Insider Sell: Peter Rahmer Sells 50,000 Shares of Relay Therapeu
Peter Rahmer, an insider at Relay Therapeutics Inc (RLAY), sold 50,000 shares on June 30, 2026, and now holds 228,913 shares. Over the past year, Rahmer has sold 121,403 shares with no purchases, part of a company-wide trend of 22 insider sells and no buys. Shares traded at $19.09, making the stock significantly overvalued according to its GF Value of $4.14.
Relay Therapeutics (RLAY) exec ESPP buy, 50K-share 10b5-1 sale
Peter Rahmer, an executive at Relay Therapeutics (RLAY), reported both a sale and an acquisition of company stock on June 30, 2026. He sold 50,000 shares at a weighted average price of $19.09 under a pre-arranged Rule 10b5-1 trading plan and simultaneously acquired 3,056 shares at $6.95 through the company's Employee Stock Purchase Plan. Following these transactions, Rahmer directly holds 225,857 shares, including restricted stock units.
RLAY (NASDAQ: RLAY) Form 144: 50,000 Performance Stock Units; 753-share sale
A Form 144 filing for Relay Therapeutics (RLAY) reports the intent related to 50,000 Performance Stock Units (PSUs) dated January 29, 2025, and discloses a recent sale of 753 common shares on April 28, 2026, for $11,136.87. The filing is considered routine and administrative, providing transparency on intended resale activity and an executed small transaction. Morgan Stanley Smith Barney LLC is listed as the broker for the transaction.
Relay Therapeutics (RLAY) Joins Multiple Russell Growth Indexes Is Its Biotech Role Being Repriced?
Relay Therapeutics (RLAY) has been added to several Russell growth indexes including the Russell 3000 Growth and Russell 2000 Growth. While this inclusion could increase visibility and liquidity, it doesn't alter the core investment narrative which is still centered on clinical progress, regulatory interactions, and managing substantial cash burn. Investors are cautioned to weigh the potential for dilution and the company's premium valuation against its clinical milestones.
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
Relay Therapeutics CFO Thomas Catinazzo sold over $3 million in company stock after exercising options, a move explained by a Rule 10b5-1 trading plan and not a shift in strategy. Despite the sale, Catinazzo retains significant equity exposure through unexercised options. The company recently reported promising Phase 2 data for zovegalisib and strengthened its balance sheet with a $275 million public offering, reinforcing its pipeline and strong stock performance.
Relay Therapeutics, Inc.(NasdaqGM:RLAY) added to Russell Small Cap Comp Growth Benchmark
Relay Therapeutics, Inc. (NasdaqGM:RLAY) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is significant for the clinical-stage biotechnology company, which focuses on developing small molecule precision medicines for cancer and genetic diseases using its Dynamo platform. The company's lead asset, zovegalisib, is currently in Phase 3 trials for metastatic breast cancer and is also being investigated for PI3Ka-driven vascular anomalies.
Why Is RLAY Stock Rising Today?
Relay Therapeutics (RLAY) shares surged by 10% in pre-market trading after announcing positive early-stage clinical data for Zovegalisib, its experimental treatment for vascular anomalies. The study showed strong efficacy with 60% of evaluable patients achieving significant lesion volume reduction and no adverse events. The company is also advancing Zovegalisib in late-stage breast cancer studies, having received Breakthrough Therapy designation from the FDA.
Relay Therapeutics, Inc. Actuals & Estimates (NASDAQ:RLAY)
This article provides an overview of Relay Therapeutics, Inc. (NASDAQ: RLAY) stock performance, forecasts, and financial data. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report. The piece also includes analyst opinions, suggesting future price estimates and technical analysis ratings.
Relay Therapeutics (RLAY) Short Interest & Short Float | Updated Jun 2026 $RLAY
As of June 15, 2026, Relay Therapeutics (RLAY) had a short interest of 38.12 million shares, representing 20.96% of its public float, marking a 10.86% increase from the prior report. The short interest ratio is 9.9 days to cover. This data indicates a significant bearish sentiment among investors towards RLAY stock, with a high percentage of float sold short.
RLAY Forecast — Price Target — Prediction for 2027
Relay Therapeutics, Inc. (RLAY) stock has seen significant growth, rising 465.34% over the last year. Analysts have provided price forecasts for RLAY, with a maximum estimate of $32.00 and a minimum of $20.00. The company is set to release its next earnings report on August 6, 2026, and its stock is currently rated as a "strong buy" by technical analysis for the upcoming month.
Relay Therapeutics president R&D sells $1.58m in stock
Donald A. Bergstrom, President, R&D at Relay Therapeutics, Inc., sold 93,456 shares of the company's common stock for over $1.58 million after exercising stock options. This transaction was executed under a Rule 10b5-1 trading plan. The sale follows recent positive news for Relay Therapeutics, including a $275 million stock offering and raised price targets from analysts due to promising Phase 2 trial results for its zovegalisib drug.
Form 4 Relay Therapeutics Inc For: 24 June By Investing.com
This article reports on a Form 4 filing for Relay Therapeutics Inc. dated June 24, 2026, as reported by Investing.com. The content is brief and primarily serves as an announcement for the filing, indicating recent financial activity for the company.
Relay Therapeutics(RLAY.US) Officer Sells US$3.18 Million in Common Stock
An officer at Relay Therapeutics (RLAY.US) recently sold 200,000 shares of common stock for a total value of $3.18 million. The transaction was executed at an average price of $15.9 per share. Following this sale, the officer's remaining stake in the company is 214,142 shares.
Relay Therapeutics (NASDAQ: RLAY) CFO sells 187,163 shares after exercising options
Relay Therapeutics' (NASDAQ: RLAY) Chief Financial Officer, Thomas Catinazzo, exercised stock options for 169,446 shares and subsequently sold 187,163 common shares in open-market transactions. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved sales at weighted average prices between $16.97 and $17.01 per share. Following these trades, Catinazzo directly holds 177,461 common shares, including restricted stock units.
Relay Therapeutics (RLAY) R&D chief exercises options and sells 93K shares
Donald A. Bergstrom, President of R&D at Relay Therapeutics (RLAY), exercised stock options for 93,456 shares at $4.12 per share and subsequently sold all of them on the open market at a weighted average price of $16.94 per share on June 22, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on October 30, 2025. Following these sales, Bergstrom directly holds 512,013 shares of common stock, including shares from restricted stock units.
Relay Therapeutics president R&D sells $1.58m in stock By Investing.com
Donald A. Bergstrom, President, R&D at Relay Therapeutics, Inc. (NASDAQ:RLAY), sold 93,456 shares for $1.58 million after exercising stock options. The sale was executed under a Rule 10b5-1 trading plan. This transaction follows recent company developments, including a $275 million stock offering and positive analyst outlooks based on favorable Phase 2 trial results for their novegalisib drug.
8-Day Rally Sends Relay Therapeutics Stock Up 29%
Relay Therapeutics stock has experienced an 8-day rally, resulting in a 29% increase in its share price. The article title provides this key financial performance update. No further details about the reasons for the rally or future outlook are given.
Relay Therapeutics stock hits 52-week high at 17.54 USD
Relay Therapeutics (RLAY) stock reached a 52-week high of $17.54, trading near its peak with a market capitalization of $3.75 billion, representing a 427.19% surge over the past year. This growth is driven by investor confidence and positive analyst ratings following strong Phase 2 trial data for its drug, zovegalisib, despite InvestingPro data suggesting potential overvaluation and high volatility. The company recently announced a $275 million stock offering and plans an additional $175 million share offering.
Relay Therapeutics stock hits 52-week high at 17.54 USD By Investing.com
Relay Therapeutics stock recently hit a 52-week high of $17.54, reflecting a significant 427.19% surge over the past year. Despite this strong performance and several recent bullish analyst ratings following positive Phase 2 trial data for zovegalisib, InvestingPro data suggests the stock might be overvalued with high volatility. The company also announced plans for two stock offerings to raise substantial capital.
Relay Therapeutics stock hits 52-week high at 17.54 USD By Investing.com
Relay Therapeutics (RLAY) stock recently hit a new 52-week high of $17.54, reflecting a significant 427.19% surge over the past year and strong investor confidence. Despite this, InvestingPro data suggests the stock might be overvalued with high volatility. The company is also planning additional stock offerings and has received increased price targets from several analysts following positive Phase 2 trial data for its drug zovegalisib.
Form 144 RELAY THERAPEUTICS For: 22 June By Investing.com
This article reports on a Form 144 filing for RELAY THERAPEUTICS (RLAY) on June 22. Form 144 filings indicate an intent to sell restricted securities, often by company insiders. The brief piece includes a stock performance note showing RLAY was up 8.82%.
Form 144 RELAY THERAPEUTICS For: 22 June By Investing.com
This article from Investing.com announces the filing of Form 144 for RELAY THERAPEUTICS on June 22. Form 144 is a notice of the intent to sell restricted securities. The brief notice highlights RELAY THERAPEUTICS and its stock symbol RLAY.
RLAY: Director Thomas Catinazzo executed 4 10b5-1 sales (Apr–May 2026)
A Form 144 filing for Relay Therapeutics (RLAY) indicates that Director Thomas J. Catinazzo executed four 10b5-1 sales in April and May 2026. The sales involved a total of 38,206 shares with proceeds totaling over $400,000. Additionally, the filing details planned dispositions including the exercise of stock options and conversions of Restricted Stock Units and Performance Stock Units.
Donald A. (RLAY) files Form 144 to sell 93,456 shares on 06/22/2026
Donald A. has filed a Form 144 to sell 93,456 shares of Relay Therapeutics (RLAY) common stock, primarily from an exercise of stock options, with a proposed sale date of June 22, 2026. The filing also notes 17,190 shares from Restricted Stock Units and a past sale of 1,490 shares on April 28, 2026, for $22,037.10. A securities lawyer assesses the filing as neutral, indicating it documents a proposed resale and that actual completion depends on market conditions and resale rules.
Relay Therapeutics Stock - Weekly review and sector context after muted news flow
Relay Therapeutics (RLAY) stock closed the week without new company-specific news, prompting investors to focus on recent price action, the broader biotech sector, and existing guidance. The company's shares last closed at $15.88 on June 18, 2026, with slight gains, and its valuation remains sensitive to data from its precision oncology programs. Relay Therapeutics uses a structure-based drug discovery platform, with its FGFR2 selective inhibitor RLY-4008 being a key clinical asset.
Relay Therapeutics Inc (RLAY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Relay Therapeutics Inc (RLAY) stock information, including its market capitalization and current trading price. It also highlights that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company, indicating a lack of detailed financial reporting in these areas. The article serves as a placeholder for future financial data.
Number of shareholders of Relay Therapeutics, Inc. – NASDAQ:RLAY
This article from TradingView provides financial information for Relay Therapeutics, Inc. (NASDAQ: RLAY), specifically focusing on its number of shareholders. It indicates that the content on shareholder numbers is available under categories like "Period," "Value," "Change," and "Change %."
Relay Therapeutics Inc (RLAY) Earnings Forecast: Future EPS & Revenue Growth Estimates
Relay Therapeutics Inc (RLAY) has an earnings forecast score of 8.92, ranking 34th in its industry, with an average price target of $14.50 based on 12 analysts. Most analysts recommend a "Buy" for RLAY stock. The company's expected revenue for the next quarter is $660.00K, and the expected EPS is -$0.39, following a reported EPS of -$0.32 in the previous quarter against an expectation of -$0.41.
Relay Therapeutics (RLAY) director Claire Mazumdar receives 32,947 stock options grant
Relay Therapeutics director Claire Mazumdar was granted 32,947 stock options with an exercise price of $14.09 per share, expiring on June 8, 2036. These options will vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual stockholders' meeting. Following this grant, Mazumdar directly holds options for 32,947 shares.
Relay Therapeutics (RLAY) Stock Valuation After Analyst Upgrades On Early Zovegalisib Data
Relay Therapeutics (RLAY) has seen recent analyst upgrades due to early positive clinical data for its drug candidate zovegalisib, particularly in vascular anomalies. Despite strong recent price momentum and trading below the average analyst price target, the stock has a high price-to-book ratio of 5x, suggesting investors are already pricing in considerable future success given the company is still reporting net losses. The article advises investors to review key rewards and warning signs to decide if a buying opportunity still exists.
Does Zovegalisib Momentum and Expanded Share Capacity Change The Bull Case For Relay Therapeutics (RLAY)?
Relay Therapeutics recently secured shareholder approval to increase its authorized common stock capacity from 300 million to 450 million shares. Concurrently, new clinical data for zovegalisib in vascular malformations has led to more positive assessments of its commercial potential, strengthening Relay's investment narrative despite ongoing financial losses. While this momentum reinforces the bull case, investors must consider the increased dilution risk and continued capital needs.
Does Zovegalisib Momentum and Expanded Share Capacity Change The Bull Case For Relay Therapeutics (RLAY)?
Relay Therapeutics recently gained shareholder approval to increase its authorized common stock capacity and simultaneously received positive initial clinical data for zovegalisib in vascular malformations. This article explores how the upgraded outlook for zovegalisib impacts Relay Therapeutics' investment narrative, acknowledging both enhanced commercial potential and ongoing dilution risks. It also highlights that despite growing analyst enthusiasm, core binary risks related to trial outcomes and funding remain.
Relay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is Why
Relay Therapeutics Inc. (RLAY) is highlighted as a top AI-driven biotech stock due to positive clinical data for its drug, zovegalisib, targeting vascular anomalies. JonesResearch upgraded RLAY from Hold to Buy with an increased price target of $20, citing clear treatment efficacy and doubling the estimated commercial success probability. Raymond James also reiterated a Strong Buy rating, raising its price target to $26, after preliminary clinical outcomes showed a 60% response rate at 12 weeks for zovegalisib in PIK3CA-driven vascular anomalies, suggesting it could be safer and more effective than existing treatments.
Relay Therapeutics (RLAY) director granted options on 32,947 shares at $14.09
Relay Therapeutics (NASDAQ: RLAY) director Alexis Borisy was granted stock options for 32,947 shares with an exercise price of $14.09 per share, expiring on June 8, 2036. This compensation-related grant vests on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual stockholders' meeting. The transaction is identified as a grant/award of derivative securities and not an open-market purchase or sale.
[Form 4] Relay Therapeutics, Inc. Insider Trading Activity
Relay Therapeutics director Linda A. Hill received a stock option grant for 32,947 shares of common stock, with an exercise price of $14.09 per share. This grant, awarded on June 9, 2026, is a compensation award and not an open-market transaction. The options vest in full on the earlier of one year from the grant date or the next annual stockholders' meeting, and they expire on June 8, 2036.
Relay Therapeutics prices $275M public offering of common stock at $12/share
Relay Therapeutics has priced a public offering of 22,916,667 shares of its common stock at $12.00 per share. The offering is expected to generate gross proceeds of approximately $275.0 million before deductions. This offering is anticipated to close around June 17, 2026.
Relay Therapeutics (NASDAQ: RLAY) ups authorized common stock to 450M
Relay Therapeutics (NASDAQ: RLAY) has increased its authorized common stock from 300 million to 450 million shares following approval from stockholders at its 2026 annual meeting. The company filed a Certificate of Second Amendment in Delaware to implement this change. Additionally, stockholders re-elected two Class III directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026.
RLAY News | RELAY THERAPEUTICS INC (NASDAQ:RLAY)
This article provides news and analysis for Relay Therapeutics Inc (NASDAQ:RLAY), including its stock price, recent earnings reports, and announcements regarding investor conferences and public offerings of common stock. Key updates include beating Q1 estimates while experiencing a wider loss, exceeding Q4 revenue estimates, and presenting initial clinical data for Zovegalisib.
Goodwin Advises Relay Therapeutics On Pricing Of $316 Million Public Offering Of Common Stock
Goodwin Procter LLP's Life Sciences team advised Relay Therapeutics on its successful public offering of 22,916,667 shares of common stock at $12 per share, raising approximately $316 million. Relay Therapeutics, a clinical-stage precision medicine company, granted underwriters an option for an additional 3,437,500 shares, which was fully exercised. The company focuses on developing therapies for cancer and genetic diseases using its Dynamo® platform, with its lead asset, zovegalisib, currently in Phase 3 clinical trials.
RLAY stock lights up on vascular anomalies treatment data boost – 60% of patients show sharp reduction in lesion volume
RLAY stock increased significantly after the company announced positive interim data for its vascular anomalies treatment. Sixty percent of patients in the ongoing study experienced a sharp reduction in lesion volume, with an average reduction of 69%. The treatment also showed improvement in pain, bleeding, and functional impairment.
RLAY Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and event updates for Relay Therapeutics (RLAY) stock. Key highlights include breakthroughs in drug trials, strong post-IPO performance, and the pricing of a public offering. The article also touches upon a recent increase in deal size.
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)
Healthcare analysts have issued bullish sentiments for Rezolute (RZLT) and Relay Therapeutics (RLAY). Wedbush maintained a Buy rating on Rezolute with a $6.00 price target, while JonesTrading reiterated a Buy rating on Relay Therapeutics with a $20.00 price target. Both companies received strong analyst consensus ratings, indicating potential upside for investors.
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)
Healthcare analysts have issued bullish ratings for Rezolute (RZLT) and Relay Therapeutics (RLAY). Wedbush maintained a Buy rating for Rezolute with a $6.00 price target, while JonesTrading reiterated a Buy rating for Relay Therapeutics with a $20.00 price target. Both companies show strong analyst consensus, with significant upside potential based on their average price targets.
Relay Therapeutics Hits Day High with 10.1% Surge in Strong Intraday Performance
Relay Therapeutics (NASDAQ:RLAY) experienced a significant 10.1% surge in its stock price on June 2, 2026, reaching an intraday high of $17.46. The company has shown impressive year-over-year growth of 393.71% and 85.58% year-to-date, despite reporting net losses. High institutional holdings at 100% indicate strong investor confidence despite the losses.
Relay Therapeutics stock hits 52-week high at 17.33 USD
Relay Therapeutics (RLAY) stock hit a 52-week high of $17.33, reflecting a 348% one-year return, despite InvestingPro data suggesting it might be overvalued. The company recently announced two public offerings to raise a total of $450 million and has received raised price targets from several analysts following positive Phase 2 trial results for its drug zovegalisib.
Relay Therapeutics stock hits 52-week high at 17.33 USD By Investing.com
Relay Therapeutics (RLAY) stock has reached a new 52-week high of $17.33, driven by investor confidence in its drug discovery approach and impressive 348% 1-year total return. Despite being potentially overvalued according to InvestingPro, the biopharmaceutical firm maintains a strong balance sheet. Recent developments include a public stock offering to raise capital and positive analyst ratings following promising Phase 2 trial results for its drug zovegalisib.
Relay Therapeutics (RLAY) Valuation Check After Promising Zovegalisib Phase 2 Vascular Anomaly Data
Relay Therapeutics recently announced positive Phase 2 data for its drug zovegalisib for PIK3CA-driven vascular anomalies, showing patient improvement. Despite strong share price performance over the last year, the company's valuation, evidenced by a Price-to-Book ratio of 4.8x compared to an industry average of 2.6x, suggests it may be overvalued, especially given its unprofitability and forecasted lack of profitability within the next three years. Investors are advised to consider the clinical progress against current valuation concerns and potential risks.
What Does Breakthrough Therapy Designation Mean for Relay Therapeutics
Relay Therapeutics' lead oncology candidate, zovegalisib, has received FDA Breakthrough Therapy Designation for specific PIK3CA-mutant advanced breast cancer, indicating accelerated development and regulatory support. This designation is supported by promising Phase 1/2 ReDiscover trial data showing strong efficacy and a favorable safety profile compared to existing treatments. A critical upcoming catalyst for investors is the presentation of Phase 1/2 data for the Phase 3 dose in March 2026, which could significantly impact the stock's trajectory.
